New incident report
Incident Report Number: 2010-0869
Registrant Reference Number: Prosar 1-20956230
Registrant Name (Full Legal Name no abbreviations): The Hartz Mountain Corporation
Address: 400 Plaza Drive
City: Secaucus
Prov / State: New Jersey
Country: USA
Postal Code: 07094-3688
Domestic Animal
Country: UNITED STATES
Prov / State: FLORIDA
PMRA Registration No. PMRA Submission No. EPA Registration No. 2596-78
Product Name: UltraGuard Flea/Tick Powder for Cats 4 oz
Dust
Yes
Unknown
Site: Animal / Usage sur un animal domestique
Unknown
Medical Professional
Cat / Chat
Domestic Shorthair
1
Female
1.25
3.8
lbs
Skin
Unknown / Inconnu
Unknown / Inconnu
System
Persisted until death
Yes
Yes
Unknown
Died
Treatment / Traitement
(eg. description of the frequency and severity of the symptoms
1-20956230: A reporter (veterinarian) called on 12/08/2009 to report the exposure of 2 cats to a flea and tick powder containing the active ingredient Tetrachlorvinphos. According to the reporter, the product was applied to the cats on 12/07/2009. An unknown time following product application, Cat #1 (1st Subform III) developed weakness, mydriasis, and nystagmus. Cat #2 (2nd Subform III) developed hypersalivation. The cats had presented to the reporter the morning of the report. The reporter was advised that the active ingredient is an organophosphate (OP) with a low order of toxicity when used appropriately. Aggressive use by an owner may result in toxicity. Signs of OP toxicity, including muscarinic and nicotinic signs, were discussed. The reporter was advised about the use of low dose atropine as a diagnostic test and how to interpret the response. A recommendation was made to bathe the cats thoroughly to decontaminate them. A recommendation was also made to treat muscarinic signs with atropine. Doses were discussed. The reporter was advised that nicotinic signs should be treated symptomatically including methocarbamol for muscle tremors and IV Valium or phenobarbital for seizures. The company's cholinesterase testing program was discussed. The reporter called back later on 12/08/2009 to report that Cat #1 had died. A recommendation was made to submit the samples for cholinesterase testing and to consider necropsy. On follow up on 12/11/2009, the reporter stated that Cat #2 had been bathed, monitored for the day and discharged. The owner had not called so the reporter assumed Cat #2 was doing well at home. The reporter called back on 12/11/2009 after speaking with the owner. Cat #2 was reportedly anorexic and had vomited on 12/10/2009. The cat was brought in for re-evaluation and was found to be euhydrated and of stable weight. The reporter was advised that the signs are not typical of OP toxicity if muscarinic and nicotinic signs had not developed. A recommendation was made to treat symptomatically. The cholinesterase testing program was again discussed. On follow up on 12/14/2009, an employee from the veterinary clinic stated that the cat was discharged on 12/12/2009. The owner had not called with any concerns since that point. No further information was obtained.
Death
Medical Professional
Cat / Chat
Unknown Breed
1
Female
Unknown
6.6
lbs
Skin
Unknown / Inconnu
Unknown / Inconnu
System
Unknown / Inconnu
Yes
Yes
Unknown
Unknown/Inconnu
Treatment / Traitement
(eg. description of the frequency and severity of the symptoms
1-20956230: A reporter (veterinarian) called on 12/08/2009 to report the exposure of 2 cats to a flea and tick powder containing the active ingredient Tetrachlorvinphos. According to the reporter, the product was applied to the cats on 12/07/2009. An unknown time following product application, Cat #1 (1st Subform III) developed weakness, mydriasis, and nystagmus. Cat #2 (2nd Subform III) developed hypersalivation. The cats had presented to the reporter the morning of the report. The reporter was advised that the active ingredient is an organophosphate (OP) with a low order of toxicity when used appropriately. Aggressive use by an owner may result in toxicity. Signs of OP toxicity, including muscarinic and nicotinic signs, were discussed. The reporter was advised about the use of low dose atropine as a diagnostic test and how to interpret the response. A recommendation was made to bathe the cats thoroughly to decontaminate them. A recommendation was also made to treat muscarinic signs with atropine. Doses were discussed. The reporter was advised that nicotinic signs should be treated symptomatically including methocarbamol for muscle tremors and IV Valium or phenobarbital for seizures. The company's cholinesterase testing program was discussed. The reporter called back later on 12/08/2009 to report that Cat #1 had died. A recommendation was made to submit the samples for cholinesterase testing and to consider necropsy. On follow up on 12/11/2009, the reporter stated that Cat #2 had been bathed, monitored for the day and discharged. The owner had not called so the reporter assumed Cat #2 was doing well at home. The reporter called back on 12/11/2009 after speaking with the owner. Cat #2 was reportedly anorexic and had vomited on 12/10/2009. The cat was brought in for re-evaluation and was found to be euhydrated and of stable weight. The reporter was advised that the signs are not typical of OP toxicity if muscarinic and nicotinic signs had not developed. A recommendation was made to treat symptomatically. The cholinesterase testing program was again discussed. On follow up on 12/14/2009, an employee from the veterinary clinic stated that the cat was discharged on 12/12/2009. The owner had not called with any concerns since that point. No further information was obtained.
Moderate